1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [95a843a0-3059-4f27-9703-150735337c0c] => Array
        (
            [runtime-id] => 95a843a0-3059-4f27-9703-150735337c0c
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [50bc063b-3d93-425d-bb1c-dbf8ed06abca] => Array
                        (
                            [runtime-id] => 50bc063b-3d93-425d-bb1c-dbf8ed06abca
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;6444cc9bd66695bc78b2f1b299c1a8b884c601bc
                )

        )

)
1naresh2naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [627e5c37-a991-4022-abb5-39b13d438745] => Array
        (
            [runtime-id] => 627e5c37-a991-4022-abb5-39b13d438745
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [6fba3d7b-7f9e-460a-a2e7-f6cfae3e99ab] => Array
                        (
                            [runtime-id] => 6fba3d7b-7f9e-460a-a2e7-f6cfae3e99ab
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;6444cc9bd66695bc78b2f1b299c1a8b884c601bc
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Takano, K.
AU  - Kinoshita, M.
AU  - Arita, H.
AU  - Okita, Y.
AU  - Chiba, Y.
AU  - Kagawa, N.
AU  - Fujimoto, Y.
AU  - Kishima, H.
AU  - Kanemura, Y.
AU  - Nonaka, M.
AU  - Nakajima, S.
AU  - Shimosegawa, E.
AU  - Hatazawa, J.
AU  - Hashimoto, N.
AU  - Yoshimine, T.
TI  - Diagnostic and Prognostic Value of &lt;sup&gt;11&lt;/sup&gt;C-Methionine PET for Nonenhancing Gliomas
AID  - 10.3174/ajnr.A4460
DP  - 2016 Jan 01
TA  - American Journal of Neuroradiology
PG  - 44--50
VI  - 37
IP  - 1
4099  - http://www.ajnr.org/content/37/1/44.short
4100  - http://www.ajnr.org/content/37/1/44.full
SO  - Am. J. Neuroradiol.2016 Jan 01; 37
AB  - BACKGROUND AND PURPOSE: Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection of malignant transformation. Although positron-emission tomography is considered valuable in the care of patients with gliomas, 18F-fluorodeoxyglucose and 11C-methionine have reportedly shown ambiguous results in terms of grading and prognostication. The present study compared the diagnostic and prognostic capabilities of diffusion tensor imaging, FDG, and 11C-methionine PET in nonenhancing gliomas.MATERIALS AND METHODS: Thirty-five consecutive newly diagnosed, histologically confirmed nonenhancing gliomas that underwent both FDG and 11C-methionine PET were retrospectively investigated (23 grade II and 12 grade III gliomas). Apparent diffusion coefficient, fractional anisotropy, and tumor-to-normal tissue ratios of both FDG and 11C-methionine PET were compared between grade II and III gliomas. Prognostic values of these parameters were also tested by using progression-free survival.RESULTS: Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor2-to-normal tissue than grade II gliomas in 11C-methionine (P = .013, P = .0017, respectively), but not in FDG-PET imaging. There was no significant difference in average ADC, minimum ADC, average fractional anisotropy, and maximum fractional anisotropy. 11C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%). Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of &amp;lt;2.0 for 11C-methionine PET and 18.6 ± 6.9 months in patients with maximum tumor-to-normal tissue ratio of &amp;gt;2.0 (P = .0044).CONCLUSIONS: 11C-methionine PET holds promise for World Health Organization grading and could offer a prognostic imaging biomarker for nonenhancing gliomas.MET11C-methioninePFSprogression-free survivalT/Ntumor-to-normal tissueT/Naveaverage tumor-to-normal tissueT/Nmaxmaximum tumor-to-normal tissue